SHE CAN'T CONTROL HER BINGES WITH WILLPOWER ALONE

Vyvanse is the first and only treatment proven to help control moderate to severe Binge Eating Disorder (B.E.D.) in adults1,2

Hypothetical patient portrayal. Individual results may vary.

A DEEPER DIVE ON DIAGNOSING B.E.D. IN ADULTS

Because there is no typical adult B.E.D. patient, it can be difficult to diagnose.3 Learn more about B.E.D. with helpful stats, patient experiences, and diagnostic criteria.

TITRATE TO THE TARGET DOSE

Based on your patient's clinical response, guide your patients through proper titration to the once-daily Vyvanse target dose to help improve their binge eating.1

Help your eligible patients start saving.

Hypothetical patient portrayal

SHOW YOUR ELIGIBLE PATIENTS HOW THEY COULD SAVE

We’re dedicated to providing a savings offer to help make Vyvanse prescriptions accessible to your eligible patients. See details. Restrictions apply.*

Hypothetical patient portrayal

KEEP IN TOUCH

Stay up to date with the latest information to help support your Vyvanse patients.

References
  1. Vyvanse [package insert]. Lexington, MA: Shire US Inc.
  2. FDA expands uses of Vyvanse to treat binge-eating disorder [news release]. U.S. Food and Drug Administration; January 30, 2015.
  3. Herman BK, Safikhani S, Hengerer D, et al. The patient experience with DSM-5-defined binge eating disorder: characteristics, barriers to treatment, and implications for primary care physicians. Postgrad Med. 2014;126(5):52‐63.

INDICATION AND IMPORTANT SAFETY INFORMATION